Middle East Journal of Cancer

HO-3867 Induces Cell Apoptosis by Reducing STAT3 Signaling in Hepatocellular Carcinoma

Articles in Press

Document Type : Original Article(s)

Authors

Zhiya Xiao
Jun Hu

Hunan Aerospace Hospital, ChangSha, China

10.30476/mejc.2026.107082.2282
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with limited treatment options. HO-3867, a STAT3 inhibitor, has shown anticancer effects in other malignancies, but its role in HCC remains unclear. This study aimed to investigate the efficacy and mechanism of HO-3867 against HCC.
Method: We conducted an experimental study combining in-vitro cell assays (proliferation, colony formation, apoptosis analysis, Western blot) using HCC cell lines and in-vivo nude mouse xenograft model, and all quantitative experimental data were statistically analyzed using unpaired two-tailed Student's t-test for comparisons between two groups and one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test for multiple group comparisons, with a P-value less than 0.05 defined as statistically significant.
Results: HO-3867 significantly inhibited HCC cell viability, colony formation, and induced apoptosis in-vitro, and suppressed tumor growth in-vivo via inhibiting STAT3 phosphorylation and downstream anti-apoptotic protein expression.
Conclusion: HO-3867 exerts potent anti-HCC effects through targeting STAT3 signaling, providing a preclinical basis for further clinical development.

Keywords

Hepatocellular carcinoma
HO-3867
STAT3
Apoptosis
Subjects

Please cite this article as: Xiao Z, Hu J. HO-3867 induces cell apoptosis by reducing STAT3 signaling in hepatocellular carcinoma. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.107082.2282.

  1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. doi: 10.1038/s41575-019-0186-y. PMID: 31439937; PMCID: PMC6813818.
  2. Koshy A. Evolving global etiology of hepatocellular carcinoma (HCC): Insights and trends for 2024. J Clin Exp Hepatol. 2025;15(1):102406. doi: 10.1016/j.jceh.2024.102406. PMID: 39346785; PMCID: PMC11426038.
  3. Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370. doi: 10.3390/cells9061370. PMID: 32492896; PMCID: PMC7349517.
  4. Bao MH, Wong CC. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715. doi: 10.3390/cells10071715. PMID: 34359884; PMCID: PMC8304710.
  5. Liu W, Zhang F, Quan B, Yao F, Chen R, Ren Z, et al. DDR2/STAT3 positive feedback loop mediates the immunosuppressive microenvironment by upregulating PD-L1 and recruiting MDSCs in oxaliplatin-resistant HCC. Cell Mol Gastroenterol Hepatol. 2024;18(4):101377. doi: 10.1016/j.jcmgh.2024.101377. PMID: 38969205; PMCID: PMC11386308.
  6. Dong S, Guo X, Han F, He Z, Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B. 2022;12(3):1163-85. doi: 10.1016/j.apsb.2021.08.020. PMID: 35530162; PMCID: PMC9069318.
  7. Naik A, Thomas R, Sikhondze M, Babiker A, Lattab B, Qasem H, et al. The LDHC-STAT3 signaling network is a key regulator of basal-like breast cancer cell survival. Cancers (Basel). 2024;16(13):2451. doi: 10.3390/cancers16132451. PMID: 39001513; PMCID: PMC11240808.
  8. Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10(13):5943-56. doi: 10.7150/thno.41498. PMID: 32483429; PMCID: PMC7254983.
  9. Ahmad N, Chen L, Yuan Z, Ma X, Yang X, Wang Y, et al. Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway. Neurotherapeutics. 2024;21(5):e00431. doi: 10.1016/j.neurot.2024.e00431. PMID: 39153914; PMCID: PMC11579875.
  10. Mast JM, Tse D, Shee K, Lakshmi Kuppusamy M, Kmiec MM, Kálai T, et al. Diarylidenylpiperidones, H-4073 and HO-3867, induce G2/M cell-cycle arrest, apoptosis and inhibit STAT3 phosphorylation in human pancreatic cancer cells. Cell Biochem Biophys. 2019;77(2):109-19. doi: 10.1007/s12013-019-00873-6. PMID: 31089934.
  11. Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. PMID: 24590057; PMCID: PMC4286190.
  12. Devor EJ, Schickling BM, Lapierre JR, Bender DP, Gonzalez-Bosquet J, Leslie KK. The synthetic curcumin analog HO-3867 rescues suppression of PLAC1 expression in ovarian cancer cells. Pharmaceuticals (Basel). 2021;14(9):942. doi: 10.3390/ph14090942. PMID: 34577642; PMCID: PMC8465575.
  13. Chen CW, Hsieh MJ, Ju PC, Hsieh YH, Su CW, Chen YL, et al. Curcumin analog HO-3867 triggers apoptotic pathways through activating JNK1/2 signalling in human oral squamous cell carcinoma cells. J Cell Mol Med. 2022;26(8):2273-84. doi: 10.1111/jcmm.17248. PMID: 35191177; PMCID: PMC8995445.
  14. Hu Y, Zhao C, Zheng H, Lu K, Shi D, Liu Z, et al. A novel STAT3 inhibitor HO-3867 induces cell apoptosis by reactive oxygen species-dependent endoplasmic reticulum stress in human pancreatic cancer cells. Anticancer Drugs. 2017;28(4):392-400. doi: 10.1097/CAD.0000000000000470. PMID: 28067673.
  15. Sanaei M, Kavoosi F. Effect of valproic acid on the class I histone deacetylase 1, 2 and 3, tumor suppressor genes p21WAF1/CIP1 and p53, and intrinsic mitochondrial apoptotic pathway, pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) apoptotic genes expression, cell viability, and apoptosis induction in hepatocellular carcinoma HepG2 cell line. Asian Pac J Cancer Prev. 2021;22(S1):89-95. doi: 10.31557/APJCP.2021.22.S1.89. PMID: 33576217.
  16. Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, et al. Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and metformin. Oncogene. 2024;43(49):3586-97. doi: 10.1038/s41388-024-03182-2. Erratum in: Oncogene. 2026;45(34):3623-6. doi: 10.1038/s41388-026-03949-9. PMID: 39414985; PMCID: PMC11602708.
  17. Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, et al. Natural products as anticancer agents: Current status and future perspectives. Molecules. 2022;27(23):8367. doi: 10.3390/molecules27238367. PMID: 36500466; PMCID: PMC9737905.
  18. Hsueh K, Ju P, Hsieh Y, Su S, Yeh C, Lin C, et al. HO-3867, a curcumin analog, elicits cell apoptosis and p38-mediated caspase activation in hepatocellular carcinoma. Environ Toxicol. 2024;39(2):794-802. doi: 10.1002/tox.23987. PMID: 37997413.
  19. Devor E J, Schickling B M, Lapierre J R, Bender D P, Gonzalez-Bosquet J, Leslie K K, et al. The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells. Pharmaceuticals (Basel). 2021;14(9):942. doi: 10.3390/pharmaceuticals14090942. PMID: 34577566; PMCID: PMC8465827.
  20. Das A, Kamran M, Ali N, et al. HO-3867 Induces ROS-Dependent Stress Response and Apoptotic Cell Death in Leishmania donovani. Front Cell Infect Microbiol. 2021;11:774899. doi: 10.3389/fcimb.2021.774899. PMID: 34976765; PMCID: PMC8718789.
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 01 April 2027

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us